Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Large B-Cell, Diffuse 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hodgkin Disease 1Glioma 1Glioblastoma 1Down Syndrome 1Astrocytoma 1

Interventions

romidepsin 5fludarabine phosphate 5Cyclosporine 5Biopsy 5tanespimycin 4Gemcitabine 4belinostat 3aldesleukin 3Vorinostat 3Polymerase Chain Reaction 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Irinotecan 3Flow Cytometry 3Busulfan 3Bortezomib 3B3(Fv)-PE38KDEL recombinant immunotoxin 3Antilymphocyte Serum 3nelarabine 2laromustine 2fludarabine 2entinostat 2alvocidib 2Specimen Handling 2Psychiatric Rehabilitation 2Pharmacogenomic Testing 2O(6)-benzylguanine 2Mycophenolic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, T-Cell, Cutaneous × Spinal Puncture × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡